Kathleen H. Chaput
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kathleen H. Chaput has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Amy Metcalfe
Department of Obstetrics and Gynecology, Cumming School of Medicine, University of Calgary, Calgary, Canada
5 shared publications- Natalie V. Scime
Department of Obstetrics and Gynecology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada
3 shared publications Suzanne C. Tough
Affiliations Department of Paediatrics, Cumming School of Medicine at University of Calgary, Calgary, AB, Canada, Department of Community Health Sciences, Cumming School of Medicine at University of Calgary, Calgary, AB, Canada
3 shared publicationsAlberto Nettel-Aguirre
Department of Community Health Sciences (Chaput, Nettel-Aguirre, Musto, Adair, Tough), Cumming School of Medicine; Department of Paediatrics (Chaput, Nettel-Aguirre, Tough), Cumming School of Medicine, University of Calgary; Alberta Health Services - Calgary Zone (Musto); Department of Psychiatry (Adair), Cumming School of Medicine, University of Calgary, Calgary, Alta
2 shared publications- Amy Metcalfe
Department of Obstetrics and Gynecology, University of Calgary, Canada; Department of Medicine, University of Calgary, Canada; Department of Community Health Sciences, University of Calgary, Canada
2 shared publications Carly A. McMorris
Werklund School of Education, School and Child Psychology, University of Calgary, Calgary, Canada
2 shared publications
Latest Publications
- Open Access
- 11 June 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (11) , e70388
A qualitative enquiry into the lived experiences of women with type 1 diabetes using closed‐loop insulin delivery in pregnancy in the CIRCUIT trial
Aims: This qualitative inquiry aimed to explore the lived experiences of pregnant women with self‐management of type 1 diabetes (T1D) using closed‐loop insulin delivery in the CIRCUIT trial 9 to provide a qualitative overview of its impacts and improve the understanding of T1D experiences in pregnancy. Methods: We used semi‐structured, individual interviews with 18 CIRCUIT randomized trial participants. Two team members analysed verbatim transcripts using inductive thematic analysis. Results: Four major themes emerged: 1. Independence and isolation; 2. Support is key; 3. Closed‐loop impacts; and 4. Control and autonomy. Diabetes management during pregnancy was an emotionally overwhelming experience that was managed largely independently. Closed‐loop was noted as a gamechanger for diabetes management during and after pregnancy. Participants felt the transition to and use of this technology would not have been possible without their healthcare team's support. Permeating all themes was the importance of control to achieve the best possible glycaemic outcomes for the health of their babies and autonomy over personal treatment decisions. The perceptions of loss of personal autonomy were associated with high anxiety. Conclusions: Managing T1D while pregnant is an independent and isolating endeavour, due to the ‘invisible labour’ involved and the lack of knowledge about T1D management in personal networks. Support from partners and care providers alleviated stress. Experiences with intrapartum care providers who had limited T1D understanding were perceived as a challenge by some for maintaining autonomy. The closed‐loop system was seen as a ‘gamechanger’ in T1D pregnancy management, with unanimous perception of positive impacts that far outweigh any challenges. Use of this closed‐loop system has potential to vastly improve pregnancy experiences among those with T1D.
- 11 June 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (11) , e70388
Open AccessA qualitative enquiry into the lived experiences of women with type 1 diabetes using closed‐loop insulin delivery in pregnancy in the CIRCUIT trial
Aims: This qualitative inquiry aimed to explore the lived experiences of pregnant women with self‐management of type 1 diabetes (T1D) using closed‐loop insulin delivery in the CIRCUIT trial 9 to provide a qualitative overview of its impacts and improve the understanding of T1D experiences in pregnancy. Methods: We used semi‐structured, individual interviews with 18 CIRCUIT randomized trial participants. Two team members analysed verbatim transcripts using inductive thematic analysis. Results: Four major themes emerged: 1. Independence and isolation; 2. Support is key; 3. Closed‐loop impacts; and 4. Control and autonomy. Diabetes management during pregnancy was an emotionally overwhelming experience that was managed largely independently. Closed‐loop was noted as a gamechanger for diabetes management during and after pregnancy. Participants felt the transition to and use of this technology would not have been possible without their healthcare team's support. Permeating all themes was the importance of control to achieve the best possible glycaemic outcomes for the health of their babies and autonomy over personal treatment decisions. The perceptions of loss of personal autonomy were associated with high anxiety. Conclusions: Managing T1D while pregnant is an independent and isolating endeavour, due to the ‘invisible labour’ involved and the lack of knowledge about T1D management in personal networks. Support from partners and care providers alleviated stress. Experiences with intrapartum care providers who had limited T1D understanding were perceived as a challenge by some for maintaining autonomy. The closed‐loop system was seen as a ‘gamechanger’ in T1D pregnancy management, with unanimous perception of positive impacts that far outweigh any challenges. Use of this closed‐loop system has potential to vastly improve pregnancy experiences among those with T1D.
- Open Access
- 4 June 2026
- Published by Springer Nature in BMC Psychology
- Vol. 14 (1)
Exploring the experiences of peer counsellors providing remote behavioural activation therapy for antenatal depression: a qualitative study
Growing evidence shows that peer-support and peer-led counselling is beneficial for people with antenatal depression, however, little is known about the experiences of peer counsellors (PCs) in providing support. Understanding PCs' experiences is essential for determining whether a peer-led model of care is appropriate for improving access to mental health support in pregnancy. This qualitative research aimed to capture the personal impact and experiences of PCs delivering Behavioral Activation Therapy for antenatal depression within a randomized trial. Participants were recruited from the Prediction, Prevention & Interventions for Preterm Birth (P3 Cohort) involved in the Peer-Administered Support for Antenatal Depression (PAAD) Trial. Data were collected through qualitative semi-structured interviews with PCs involved in the P3 PAAD Trial. Guided by an experience-based framework, inductive thematic analysis was employed to explore the perceptions and experiences of peer counsellors with training and delivering peer counselling to pregnant Albertans. Five themes were generated, (1) Positive Fulfillment (2) Personal Growth and Learning, (3) Fostering Dialogue on Maternal Mental Health, (4) Connection and (5) Support. PCs found fulfillment in providing support, witnessing personal growth in mentees, and expressing a desire to continue their involvement. PCs experienced mutual learning with mentees, benefitted from applying learned skills to their own daily lives, and in some cases, recognized a need to further their own treatment. PCs confronted stigma and facilitated open discussions about maternal mental health while finding solidarity and support through meaningful connections with mentees and fellow counsellors. PCs felt emotionally supported, with resources and guidance readily available. Providing peer-led counselling was perceived as largely beneficial, and the results indicate that peer-led antenatal mental health support can be beneficial to those providing the support in addition to those receiving it. These findings also support further exploration of a peer-led model of care as a potential approach for improving access to antenatal mental health support.
- 4 June 2026
- Published by Springer Nature in BMC Psychology
- Vol. 14 (1)
Open AccessExploring the experiences of peer counsellors providing remote behavioural activation therapy for antenatal depression: a qualitative study
Growing evidence shows that peer-support and peer-led counselling is beneficial for people with antenatal depression, however, little is known about the experiences of peer counsellors (PCs) in providing support. Understanding PCs' experiences is essential for determining whether a peer-led model of care is appropriate for improving access to mental health support in pregnancy. This qualitative research aimed to capture the personal impact and experiences of PCs delivering Behavioral Activation Therapy for antenatal depression within a randomized trial. Participants were recruited from the Prediction, Prevention & Interventions for Preterm Birth (P3 Cohort) involved in the Peer-Administered Support for Antenatal Depression (PAAD) Trial. Data were collected through qualitative semi-structured interviews with PCs involved in the P3 PAAD Trial. Guided by an experience-based framework, inductive thematic analysis was employed to explore the perceptions and experiences of peer counsellors with training and delivering peer counselling to pregnant Albertans. Five themes were generated, (1) Positive Fulfillment (2) Personal Growth and Learning, (3) Fostering Dialogue on Maternal Mental Health, (4) Connection and (5) Support. PCs found fulfillment in providing support, witnessing personal growth in mentees, and expressing a desire to continue their involvement. PCs experienced mutual learning with mentees, benefitted from applying learned skills to their own daily lives, and in some cases, recognized a need to further their own treatment. PCs confronted stigma and facilitated open discussions about maternal mental health while finding solidarity and support through meaningful connections with mentees and fellow counsellors. PCs felt emotionally supported, with resources and guidance readily available. Providing peer-led counselling was perceived as largely beneficial, and the results indicate that peer-led antenatal mental health support can be beneficial to those providing the support in addition to those receiving it. These findings also support further exploration of a peer-led model of care as a potential approach for improving access to antenatal mental health support.
- Open Access
- 23 May 2024
- Published by Elsevier in JAACAP Open
- Vol. 2 (4) , 250-262
Evaluation of the Association Between Prenatal Cannabis Use and Risk of Developmental Delay
- 23 May 2024
- Published by Elsevier in JAACAP Open
- Vol. 2 (4) , 250-262
Open AccessEvaluation of the Association Between Prenatal Cannabis Use and Risk of Developmental Delay
- Open Access
- 16 April 2024
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 24 (1) , 1-12
Development and validation of the Cannabis Exposure in Pregnancy Tool (CEPT): a mixed methods study
Background: Evidence of associations between prenatal cannabis use (PCU) and maternal and infant health outcomes remains conflicting amid broad legalization of cannabis across Canada and 40 American states. A critical limitation of existing evidence lies in the non-standardized and crude measurement of prenatal cannabis use (PCU), resulting in high risk of misclassification bias. We developed a standardized tool to comprehensively measure prenatal cannabis use in pregnant populations for research purposes. Methods: We conducted a mixed-methods, patient-oriented tool development and validation study, using a bias-minimizing process. Following an environmental scan and critical appraisal of existing prenatal substance use tools, we recruited pregnant participants via targeted social media advertising and obstetric clinics in Alberta, Canada. We conducted individual in-depth interviews and cognitive interviewing in separate sub-samples, to develop and refine our tool. We assessed convergent and discriminant validity internal consistency and 3-month test–retest reliability, and validated the tool externally against urine-THC bioassays. Results: Two hundred fifty four pregnant women participated. The 9-item Cannabis Exposure in Pregnancy Tool (CEPT) had excellent discriminant (Cohen’s kappa = -0.27–0.15) and convergent (Cohen’s kappa = 0.72–1.0) validity; as well as high internal consistency (Chronbach’s alpha = 0.92), and very good test–retest reliability (weighted Kappa = 0.92, 95% C.I. [0.86–0.97]). The CEPT is valid against urine THC bioassay (sensitivity = 100%, specificity = 82%). Conclusion: The CEPT is a novel, valid and reliable measure of frequency, timing, dose, and mode of PCU, in a contemporary sample of pregnant women. Using CEPT (compared to non-standardized tools) can improve measurement accuracy, and thus the quality of research examining PCU and maternal and child health outcomes.
- 16 April 2024
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 24 (1) , 1-12
Open AccessDevelopment and validation of the Cannabis Exposure in Pregnancy Tool (CEPT): a mixed methods study
Background: Evidence of associations between prenatal cannabis use (PCU) and maternal and infant health outcomes remains conflicting amid broad legalization of cannabis across Canada and 40 American states. A critical limitation of existing evidence lies in the non-standardized and crude measurement of prenatal cannabis use (PCU), resulting in high risk of misclassification bias. We developed a standardized tool to comprehensively measure prenatal cannabis use in pregnant populations for research purposes. Methods: We conducted a mixed-methods, patient-oriented tool development and validation study, using a bias-minimizing process. Following an environmental scan and critical appraisal of existing prenatal substance use tools, we recruited pregnant participants via targeted social media advertising and obstetric clinics in Alberta, Canada. We conducted individual in-depth interviews and cognitive interviewing in separate sub-samples, to develop and refine our tool. We assessed convergent and discriminant validity internal consistency and 3-month test–retest reliability, and validated the tool externally against urine-THC bioassays. Results: Two hundred fifty four pregnant women participated. The 9-item Cannabis Exposure in Pregnancy Tool (CEPT) had excellent discriminant (Cohen’s kappa = -0.27–0.15) and convergent (Cohen’s kappa = 0.72–1.0) validity; as well as high internal consistency (Chronbach’s alpha = 0.92), and very good test–retest reliability (weighted Kappa = 0.92, 95% C.I. [0.86–0.97]). The CEPT is valid against urine THC bioassay (sensitivity = 100%, specificity = 82%). Conclusion: The CEPT is a novel, valid and reliable measure of frequency, timing, dose, and mode of PCU, in a contemporary sample of pregnant women. Using CEPT (compared to non-standardized tools) can improve measurement accuracy, and thus the quality of research examining PCU and maternal and child health outcomes.
- Open Access
- 30 March 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-13
Effect of Remote Peer-Counsellor- delivered Behavioral Activation and Peer-support for Antenatal Depression on Gestational Age at Delivery: a single-blind, randomized control trial
Background: Antenatal depression (AD) is the most common complication of pregnancy in developed countries and increases the risk of preterm birth (PTB). Many pregnant individuals with AD do not obtain treatment due in part to risks associated with antidepressant medications, the expense and wait times for psychological services, and perceived stigma. Accessible and timely treatment of antenatal depression is crucial to minimize foetal impacts and associated long-term child health outcomes. Previous studies show that behavioural activation and peer support are promising avenues of treatment for perinatal depression. Additionally, remote and paraprofessional counselling interventions show promise as more accessible, sustainable, and cost-effective treatment avenues than traditional psychological services. The primary aim of this trial is to test the effectiveness of a remote, behavioural activation and peer support intervention, administered by trained peer para-professionals, for increasing gestational age at delivery among those with antenatal depression. The secondary aims are to evaluate the effectiveness for treating AD prior to delivery, with persistence into the postpartum; improving anxiety symptoms; and improving parenting self-efficacy compared to controls. Methods: A two-arm, single-blinded, parallel groups randomized controlled trial (RCT) with repeated measures will be conducted. Participants scoring >10 on the Edinburgh Postnatal Depression Scale will be recruited from the larger P3 cohort and invited to enroll. Assessments will be conducted prior to 27 weeks’ gestation at trial intake (T1), post-intervention, prior to delivery (T2), 5–6 months postpartum (T3), and 11–12 months postpartum (T4) and will include self-report questionnaires and linked medical records. Discussion: Our remote, peer paraprofessional-delivered behavioural activation plus peer support intervention has the potential to successfully reduce symptoms of AD, which may in turn decrease the risk of PTB and subsequent health impacts. The current trial builds on previous findings and uses a patient-oriented approach to address priorities for patient care and to provide a cost-effective, accessible, and evidence-based treatment to pregnant individuals with AD. Trial registration: International Standard Randomised Controlled Trial Number (ISRCTN) registry (ISRCTN51098220) ISRCTN51098220. Registered on April 7, 2022.
- 30 March 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-13
Open AccessEffect of Remote Peer-Counsellor- delivered Behavioral Activation and Peer-support for Antenatal Depression on Gestational Age at Delivery: a single-blind, randomized control trial
Background: Antenatal depression (AD) is the most common complication of pregnancy in developed countries and increases the risk of preterm birth (PTB). Many pregnant individuals with AD do not obtain treatment due in part to risks associated with antidepressant medications, the expense and wait times for psychological services, and perceived stigma. Accessible and timely treatment of antenatal depression is crucial to minimize foetal impacts and associated long-term child health outcomes. Previous studies show that behavioural activation and peer support are promising avenues of treatment for perinatal depression. Additionally, remote and paraprofessional counselling interventions show promise as more accessible, sustainable, and cost-effective treatment avenues than traditional psychological services. The primary aim of this trial is to test the effectiveness of a remote, behavioural activation and peer support intervention, administered by trained peer para-professionals, for increasing gestational age at delivery among those with antenatal depression. The secondary aims are to evaluate the effectiveness for treating AD prior to delivery, with persistence into the postpartum; improving anxiety symptoms; and improving parenting self-efficacy compared to controls. Methods: A two-arm, single-blinded, parallel groups randomized controlled trial (RCT) with repeated measures will be conducted. Participants scoring >10 on the Edinburgh Postnatal Depression Scale will be recruited from the larger P3 cohort and invited to enroll. Assessments will be conducted prior to 27 weeks’ gestation at trial intake (T1), post-intervention, prior to delivery (T2), 5–6 months postpartum (T3), and 11–12 months postpartum (T4) and will include self-report questionnaires and linked medical records. Discussion: Our remote, peer paraprofessional-delivered behavioural activation plus peer support intervention has the potential to successfully reduce symptoms of AD, which may in turn decrease the risk of PTB and subsequent health impacts. The current trial builds on previous findings and uses a patient-oriented approach to address priorities for patient care and to provide a cost-effective, accessible, and evidence-based treatment to pregnant individuals with AD. Trial registration: International Standard Randomised Controlled Trial Number (ISRCTN) registry (ISRCTN51098220) ISRCTN51098220. Registered on April 7, 2022.
- Open Access
- 27 January 2023
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 102 (4) , 420-429
Association of postpartum medication practices with early breastfeeding cessation among mothers with chronic conditions: A prospective cohort study
Introduction: Use of medications is a common concern for breastfeeding women, particularly when they are strongly needed or unavoidable to manage maternal chronic conditions. Yet the influence of medication usage patterns on breastfeeding duration in mothers with chronic conditions is unclear. The objective of this study was to examine whether postpartum medication practices were associated with shorter breastfeeding duration or earlier than planned breastfeeding cessation among mothers with chronic conditions.Material and methods: We analyzed 346 mothers with chronic conditions enrolled in a prospective, community‐based pregnancy cohort study (Alberta, Canada) who initiated breastfeeding after birth. Data were collected through self‐report questionnaires spanning late pregnancy to 6 months postpartum. Based on reported use of preexisting medications while breastfeeding, women were classified as continuing medications (reference group), discontinuing one or more medications, or those who did not use preexisting medications. Cox proportional hazards regression was used to analyze the association of medication practices and overall breastfeeding duration in weeks. Logistic regression was used to analyze the association of medication practices and earlier than planned breastfeeding cessation. Multivariable models adjusted for demographic and health‐related factors.Results: Overall, 30.6% of women with chronic conditions stopped breastfeeding in the first 6 months, almost all of whom did so earlier than planned. In multivariable models, medication discontinuation was significantly associated with shorter breastfeeding duration (adjusted hazard ratio [HR] 1.67, 95% confidence interval [CI] 1.03–2.70) and earlier than planned breastfeeding cessation (adjusted odds ratio [OR] 1.85, 95% CI 1.01–3.42), whereas medication non‐use was not associated with differences in breastfeeding outcomes.Conclusions: Women with chronic conditions who discontinued preexisting medications while breastfeeding had significantly shorter breastfeeding duration and were less likely to meet their breastfeeding goals in the first 6 months postpartum compared to women who continued preexisting medications.
- 27 January 2023
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 102 (4) , 420-429
Open AccessAssociation of postpartum medication practices with early breastfeeding cessation among mothers with chronic conditions: A prospective cohort study
Introduction: Use of medications is a common concern for breastfeeding women, particularly when they are strongly needed or unavoidable to manage maternal chronic conditions. Yet the influence of medication usage patterns on breastfeeding duration in mothers with chronic conditions is unclear. The objective of this study was to examine whether postpartum medication practices were associated with shorter breastfeeding duration or earlier than planned breastfeeding cessation among mothers with chronic conditions.Material and methods: We analyzed 346 mothers with chronic conditions enrolled in a prospective, community‐based pregnancy cohort study (Alberta, Canada) who initiated breastfeeding after birth. Data were collected through self‐report questionnaires spanning late pregnancy to 6 months postpartum. Based on reported use of preexisting medications while breastfeeding, women were classified as continuing medications (reference group), discontinuing one or more medications, or those who did not use preexisting medications. Cox proportional hazards regression was used to analyze the association of medication practices and overall breastfeeding duration in weeks. Logistic regression was used to analyze the association of medication practices and earlier than planned breastfeeding cessation. Multivariable models adjusted for demographic and health‐related factors.Results: Overall, 30.6% of women with chronic conditions stopped breastfeeding in the first 6 months, almost all of whom did so earlier than planned. In multivariable models, medication discontinuation was significantly associated with shorter breastfeeding duration (adjusted hazard ratio [HR] 1.67, 95% confidence interval [CI] 1.03–2.70) and earlier than planned breastfeeding cessation (adjusted odds ratio [OR] 1.85, 95% CI 1.01–3.42), whereas medication non‐use was not associated with differences in breastfeeding outcomes.Conclusions: Women with chronic conditions who discontinued preexisting medications while breastfeeding had significantly shorter breastfeeding duration and were less likely to meet their breastfeeding goals in the first 6 months postpartum compared to women who continued preexisting medications.
- Open Access
- 14 December 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (12) , e0279072
Second trimester cytokine profiles associated with gestational diabetes and hypertensive disorders of pregnancy
Healthy pregnancy requires a coordinated immune response, yet complications can arise, putting both the mother’s and child’s health at risk. Hypertensive disorders of pregnancy (HDP) and gestational diabetes mellitus (GDM) are pregnancy-related complications that account for most maternal morbidity and mortality. Cytokines are proteins released as part of the immune response to disease or infection and regulate inflammation. Certain pregnancy complications cause localized and systemic inflammation; however, cytokine profiles specific to such complications are not well understood. This study aims to examine associations between pregnancy complications of HDP and GDM and cytokine profiles in the second trimester of pregnancy. Data was obtained from the All Our Families birth cohort in Calgary, Alberta, Canada. The cohort collected questionnaires at the time of participant enrollment and maternal blood samples at 17–23 weeks gestation. Cases of HDP (n = 27) and GDM (n = 31) were matched to controls on BMI, maternal age, and smoking status in the preconception period at a 1:3 ratio. Cytokine levels were measured in blood samples using Luminex xMAP technology using a panel of 42 cytokines. Using R software, a Classification and Regression Tree (CART) analysis was conducted to identify cytokine profiles and levels associated with each complication. Four cytokines were identified in the HDP CART (in descending order of importance): Monocyte Chemoattractant Protein-1 (cut-off: <480pg/mL), Macrophage Inflammatory Protein-1β (cut-off: ≥26pg/mL), Eotaxin (cut-off: <27/≥27&<36/≥36pg/mL), and Soluble Cluster of Differentiation 40 Ligand (cut-off: <1342pg/mL). Six cytokine levels were identified in the GDM CART: Interleukin-1 Receptor Antagonist (IL-1Ra; cut-off: <25pg/mL), Interleukin-5 (cut-off: ≥0.4pg/mL), Interferon-γ (cut-off: <4.9pg/mL), IL-1Ra (cut-off: ≥111pg/mL), Eotaxin (cut-off: ≥21pg/mL), and Interleukin-18 (cut-off: ≥155pg/mL). By examining the complex inter-relationships between cytokines, findings of cytokine profiles guide further research in identifying biomarkers of pregnancy complications relevant to the design of the future management or prevention of these conditions.
- 14 December 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (12) , e0279072
Open AccessSecond trimester cytokine profiles associated with gestational diabetes and hypertensive disorders of pregnancy
Healthy pregnancy requires a coordinated immune response, yet complications can arise, putting both the mother’s and child’s health at risk. Hypertensive disorders of pregnancy (HDP) and gestational diabetes mellitus (GDM) are pregnancy-related complications that account for most maternal morbidity and mortality. Cytokines are proteins released as part of the immune response to disease or infection and regulate inflammation. Certain pregnancy complications cause localized and systemic inflammation; however, cytokine profiles specific to such complications are not well understood. This study aims to examine associations between pregnancy complications of HDP and GDM and cytokine profiles in the second trimester of pregnancy. Data was obtained from the All Our Families birth cohort in Calgary, Alberta, Canada. The cohort collected questionnaires at the time of participant enrollment and maternal blood samples at 17–23 weeks gestation. Cases of HDP (n = 27) and GDM (n = 31) were matched to controls on BMI, maternal age, and smoking status in the preconception period at a 1:3 ratio. Cytokine levels were measured in blood samples using Luminex xMAP technology using a panel of 42 cytokines. Using R software, a Classification and Regression Tree (CART) analysis was conducted to identify cytokine profiles and levels associated with each complication. Four cytokines were identified in the HDP CART (in descending order of importance): Monocyte Chemoattractant Protein-1 (cut-off: <480pg/mL), Macrophage Inflammatory Protein-1β (cut-off: ≥26pg/mL), Eotaxin (cut-off: <27/≥27&<36/≥36pg/mL), and Soluble Cluster of Differentiation 40 Ligand (cut-off: <1342pg/mL). Six cytokine levels were identified in the GDM CART: Interleukin-1 Receptor Antagonist (IL-1Ra; cut-off: <25pg/mL), Interleukin-5 (cut-off: ≥0.4pg/mL), Interferon-γ (cut-off: <4.9pg/mL), IL-1Ra (cut-off: ≥111pg/mL), Eotaxin (cut-off: ≥21pg/mL), and Interleukin-18 (cut-off: ≥155pg/mL). By examining the complex inter-relationships between cytokines, findings of cytokine profiles guide further research in identifying biomarkers of pregnancy complications relevant to the design of the future management or prevention of these conditions.
- Open Access
Development and Validation of the Cannabis Exposure in Pregnancy Tool (CEPT)
Background: Evidence of associations between prenatal cannabis use (PCU) and maternal and infant health outcomes remains conflicting amid broad legalization of cannabis across Canada and 40 American states. A critical limitation of existing evidence lies in the non-standardized and crude measurement of PCU, resulting in high risk of misclassification bias. We developed a standardized tool to comprehensively measure prenatal cannabis use in pregnant populations for research purposes. Methods: We conducted a patient-oriented tool development and validation study using a bias-minimizing process. Following an environmental scan and critical appraisal of existing prenatal substance use tools, we recruited pregnant participants via targeted social media advertising and obstetric clinics in Alberta, Canada. We conducted individual in-depth interviews and cognitive interviewing in separate sub-samples, to develop and refine our tool. We assessed convergent and discriminant validity internal consistency and 3-month test-retest reliability, and validated the tool externally against urine THC bioassay. Results: 254 pregnant women participated. The 9-item Cannabis Exposure in Pregnancy Tool (CEPT) had excellent discriminant (Cohen’s kappa=-0.27-0.15) and convergent (Cohen’s kappa=0.72-1.0) validity; as well as high internal consistency (Chronbach’s alpha = 0.92), and very good test-retest reliability (weighted Kappa=0.92, 95% C.I. [0.86-0.97]). The CEPT is valid against urine THC bioassay (sensitivity=100%, specificity=77%). Interpretation: The CEPT is a novel, valid and reliable measure of frequency, timing, dose, and mode of PCU, in a contemporary sample of pregnant women. Using CEPT (compared to non-standardized tools) can improve measurement accuracy, and thus the quality of PCU and maternal and child health research.
Open AccessDevelopment and Validation of the Cannabis Exposure in Pregnancy Tool (CEPT)
Background: Evidence of associations between prenatal cannabis use (PCU) and maternal and infant health outcomes remains conflicting amid broad legalization of cannabis across Canada and 40 American states. A critical limitation of existing evidence lies in the non-standardized and crude measurement of PCU, resulting in high risk of misclassification bias. We developed a standardized tool to comprehensively measure prenatal cannabis use in pregnant populations for research purposes. Methods: We conducted a patient-oriented tool development and validation study using a bias-minimizing process. Following an environmental scan and critical appraisal of existing prenatal substance use tools, we recruited pregnant participants via targeted social media advertising and obstetric clinics in Alberta, Canada. We conducted individual in-depth interviews and cognitive interviewing in separate sub-samples, to develop and refine our tool. We assessed convergent and discriminant validity internal consistency and 3-month test-retest reliability, and validated the tool externally against urine THC bioassay. Results: 254 pregnant women participated. The 9-item Cannabis Exposure in Pregnancy Tool (CEPT) had excellent discriminant (Cohen’s kappa=-0.27-0.15) and convergent (Cohen’s kappa=0.72-1.0) validity; as well as high internal consistency (Chronbach’s alpha = 0.92), and very good test-retest reliability (weighted Kappa=0.92, 95% C.I. [0.86-0.97]). The CEPT is valid against urine THC bioassay (sensitivity=100%, specificity=77%). Interpretation: The CEPT is a novel, valid and reliable measure of frequency, timing, dose, and mode of PCU, in a contemporary sample of pregnant women. Using CEPT (compared to non-standardized tools) can improve measurement accuracy, and thus the quality of PCU and maternal and child health research.
- 28 July 2022
- Published by Springer Nature in Canadian Journal of Public Health
- Vol. 114 (1) , 104-112
Association of Caesarean delivery and breastfeeding difficulties during the delivery hospitalization: a community-based cohort of women and full-term infants in Alberta, Canada
Breastfeeding difficulties are the most common reason for breastfeeding cessation, particularly in the early postpartum. Caesarean delivery is associated w
- 28 July 2022
- Published by Springer Nature in Canadian Journal of Public Health
- Vol. 114 (1) , 104-112
Association of Caesarean delivery and breastfeeding difficulties during the delivery hospitalization: a community-based cohort of women and full-term infants in Alberta, Canada
Breastfeeding difficulties are the most common reason for breastfeeding cessation, particularly in the early postpartum. Caesarean delivery is associated w
- Open Access
Contemporary social context and patterns of prenatal cannabis use in Canada following legalization: a secondary analysis of prospective cohort data
Background: The epidemiology of prenatal cannabis use in Canada following legalization remains unknown despite increasing evidence for associated health risks. Our study aimed to identify current risk factors for, and patterns of, prenatal cannabis use and second-hand cannabis exposure in Alberta. Methods: We conducted a secondary analysis of prospective data from a 2019 study in Calgary AB, of 153 pregnant (<28 weeks gestation at enrollment), English-speaking Alberta residents. We conducted descriptive analyses of prenatal cannabis use patterns (timing, frequency, dose, modes and reasons for use) and logistic regression to identify risk factors for direct use and second-hand exposure. Results: Odds of prenatal cannabis use were significantly higher among those who did not own their home (Odds Ratio (OR) 3.1; 95% CI:1.6-9.6), smoked tobacco prenatally (OR 3.3,95% CI:1.2-9.3) and used illicit substances in the past (OR 3.2; 95% CI:1.7-9.9), and lower for those consuming alcohol prenatally (OR 0.3, 0.12-0.89). Among the 90 (58%) participants who used cannabis prenatally, the majority used for medicinal reasons (96%), at least daily (67%), by smoking (88%), in all trimesters of pregnancy (66%). Although reported dose-per-use was commonly low, cumulative doses over pregnancy were high. Interpretation: Our study finds marked differences in prenatal cannabis use risk factors, and patterns of more frequent use sustained throughout pregnancy with perceived medicinal indications than pre-legalization studies. Prenatal care providers should include cannabis explicitly in medication counselling. Further prospective studies are needed as the impacts of prenatal cannabis on maternal and infant health in Canada may currently be underestimated.
Open AccessContemporary social context and patterns of prenatal cannabis use in Canada following legalization: a secondary analysis of prospective cohort data
Background: The epidemiology of prenatal cannabis use in Canada following legalization remains unknown despite increasing evidence for associated health risks. Our study aimed to identify current risk factors for, and patterns of, prenatal cannabis use and second-hand cannabis exposure in Alberta. Methods: We conducted a secondary analysis of prospective data from a 2019 study in Calgary AB, of 153 pregnant (<28 weeks gestation at enrollment), English-speaking Alberta residents. We conducted descriptive analyses of prenatal cannabis use patterns (timing, frequency, dose, modes and reasons for use) and logistic regression to identify risk factors for direct use and second-hand exposure. Results: Odds of prenatal cannabis use were significantly higher among those who did not own their home (Odds Ratio (OR) 3.1; 95% CI:1.6-9.6), smoked tobacco prenatally (OR 3.3,95% CI:1.2-9.3) and used illicit substances in the past (OR 3.2; 95% CI:1.7-9.9), and lower for those consuming alcohol prenatally (OR 0.3, 0.12-0.89). Among the 90 (58%) participants who used cannabis prenatally, the majority used for medicinal reasons (96%), at least daily (67%), by smoking (88%), in all trimesters of pregnancy (66%). Although reported dose-per-use was commonly low, cumulative doses over pregnancy were high. Interpretation: Our study finds marked differences in prenatal cannabis use risk factors, and patterns of more frequent use sustained throughout pregnancy with perceived medicinal indications than pre-legalization studies. Prenatal care providers should include cannabis explicitly in medication counselling. Further prospective studies are needed as the impacts of prenatal cannabis on maternal and infant health in Canada may currently be underestimated.